Safety Study of MGA271 in Refractory Cancer



Status:Active, not recruiting
Conditions:Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Skin Cancer, Ovarian Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Brain Cancer, Pancreatic Cancer, Bladder Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/30/2019
Start Date:July 2011
End Date:June 2019

Use our guide to learn which trials are right for you!

A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer

The purpose of this study is to evaluate the safety of MGA271 when given by intravenous (IV)
infusion to patients with refractory cancer. The study will also evaluate how long MGA271
stays in the blood and how long it takes for it to leave the body, what is the highest dose
that can safely be given, and whether it may have an effect on tumors.

An open-label, multi-dose, single-arm, multi-center, Phase 1, dose-escalation study will be
conducted to define the toxicity profile, maximum tolerated dose (MTD), pharmacokinetics
(PK), immunogenicity, and potential antitumor activity of MGA271 in patients with refractory
cancer that expresses B7-H3.

In the initial segments of the study, patients will be monitored for a minimum of four weeks
after administration of the final dose of MGA271. Study assessments will include adverse
event (AE) monitoring, electrocardiogram (ECG) monitoring, PK analysis of serum MGA271,
determination of the serum concentration of soluble MGA271 and tumor markers, and an
assessment of potential anti-MGA271 antibody [human anti-human antibody (HAHA)] response.

Tumor response assessments using Study Day 43 CT scans or MRI will be performed approximately
six weeks after the first MGA271 dose for each patient. Patients with evidence of clinical
benefit (partial or complete response or stable disease by RECIST or RANO Response criteria)
will be allowed to continue therapy at the same dose, or at a reduced dose if warranted by
dose limiting toxicity (DLT) or significant AE in Cycle 1. Subsequent cycles which will begin
on Study Day 50 will consist of MGA271 administration on Study Days 1, 8, and 15 of each
28-day cycle, with tumor evaluation every other cycle. Responding patients may receive
continued antibody therapy until evidence of progression of disease is documented or the
patient experiences DLT.

In the Expansion Segment of the study, patients will receive weekly, uninterrupted infusions
with an initial response assessment at 8 weeks. Tumor evaluation will be carried out by both
RECIST and immune-related response criteria (irRC).

Inclusion Criteria:

- Histologically or cytologically confirmed carcinoma (prostate cancer, renal cell
carcinoma, head and neck cancer, triple-negative breast cancer, bladder cancer,
non-small cell lung cancer) or melanoma that overexpresses B7-H3.

- Progressive disease during or after last treatment regimen.

- Appropriate treatment history for histological entity.

- ECOG Performance Status <= 1.

- Life expectancy >= 3 months.

- Measurable disease or evaluable disease with relevant tumor marker elevation.

- Acceptable laboratory parameters and adequate organ reserve.

Exclusion Criteria:

- Major surgery or trauma within four weeks before enrollment.

- Known hypersensitivity to murine or recombinant proteins, polysorbate 80, or any
excipient contained in the drug formulation.

- Grade 3 colitis, hepatitis, pneumonitis uveitis, myocarditis, myositis, CNS toxicity
or autoimmune related neuromuscular toxicity such as myasthenia gravis associated with
the administration of an immune checkpoint inhibitor

- Second primary malignancy that has not been in remission for greater than 3 years.
Treated non-melanoma skin cancer, cervical carcinoma in situ on biopsy, or squamous
intraepithelial lesion on PAP smear, localized prostate cancer (Gleason score < 6), or
resected melanoma in situ are exceptions and do not require a 3 year remission.

- Active viral, bacterial, or systemic fungal infection requiring parenteral treatment
within four weeks of enrollment. Patients requiring any oral antiviral, fungal, or
bacterial therapy must have completed treatment within one week of enrollment.

- Vaccination within 2 weeks of enrollment (except for annual flu vaccine).

- History of chronic or recurrent infections that require continual use of antiviral,
antifungal, or antibacterial agents.
We found this trial at
12
sites
55 Fruit St
Boston, Massachusetts 02114
(617) 724-4000
Principal Investigator: Gregory Cote, MD, PhD
Phone: 617-724-4800
Massachusetts General Hospital Cancer Center An integral part of one of the world
?
mi
from
Boston, MA
Click here to add this to my saved trials
5801 South Ellis Avenue
Chicago, Illinois 60637
 773.702.1234
Principal Investigator: Russell Szmulewitz, MD
Phone: 773-702-9136
University of Chicago One of the world's premier academic and research institutions, the University of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
9801 W. Kincey Ave
Huntersville, North Carolina 28078
704-947-6599
Principal Investigator: John D. Powderly, M.D.
?
mi
from
Huntersville, NC
Click here to add this to my saved trials
Baltimore, Maryland 20742
(301) 405-1000
Principal Investigator: Heather D. Mannuel, MD, MBA
Phone: 410-328-8610
University of Maryland As a globally-connected university offering a world-class education, the University of Maryland...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Geoffrey Shapiro, MD, PhD
Phone: 617-632-6623
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
800 Washington Street
Boston, Massachusetts 02111
Principal Investigator: John K. Erban, M.D.
Phone: 617-636-5000
?
mi
from
Boston, MA
Click here to add this to my saved trials
Los Angeles, California 90095
Principal Investigator: Bartosz Chmielowski, MD, PhD
Phone: 310-829-5471
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Louisville, Kentucky 40207
Principal Investigator: Arash Rezazadeh Kalebasty, MD
Phone: 502-629-3538
?
mi
from
Louisville, KY
Click here to add this to my saved trials
3322 West End Avenue
Nashville, Tennessee 37203
(615)329-SCRI (7274)
Principal Investigator: Howard Burris, MD
Phone: 615-339-4214
Sarah Cannon Research Institute Sarah Cannon Research Institute (SCRI) is a global strategic research organization...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
333 Cedar Street
New Haven, Connecticut 06520
(203) 785-4095
Principal Investigator: Mario Sznol, MD
Phone: 203-737-5381
Yale Cancer Center Yale Cancer Center combines a tradition of innovative cancer treatment and quality...
?
mi
from
New Haven, CT
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
Principal Investigator: Roger Cohen, M.D.
Phone: 215-662-7452
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Tampa, Florida 33612
Principal Investigator: Joseph Markowitz, M.D, PhD
Phone: 813-745-8352
?
mi
from
Tampa, FL
Click here to add this to my saved trials